Congress mandates Alzheimer's blood tests for all insured Americans
H.R. 9823 — Alzheimer’s Early Detection Act of 2026 · Filed by Jake Auchincloss (D-MA) · 2 cosponsors · Introduced Jul 22, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires private health insurance plans and Medicaid to cover Alzheimer's biomarker testing (blood tests and genetic analysis that detect early signs of Alzheimer's disease) without restrictive cost-sharing, prior authorization delays, or step-therapy requirements. It applies the same coverage rules to all insurance types and mandates equitable access for rural and underserved populations, with a one-year implementation window.
Why we flagged it
The bill's core mechanism is a coverage mandate — it requires insurers and Medicaid to pay for a specific diagnostic service without cost-sharing or procedural barriers. This is a regulatory expansion of insurance obligations, not a tax measure, subsidy, or deregulation.
What the text implies
- Biomarker testing definition is broad and includes emerging tests (whole genome/exome sequencing) not yet FDA-approved, potentially creating coverage obligations for tests still in development or with unclear clinical utility.
- The bill ties coverage to 'applicable clinical practice guidelines or consensus statements' without specifying which organizations set these standards, creating potential for industry-captured guideline bodies to expand covered tests beyond evidence-based scope.
The full analysis lists 5 implications of this text.
Who stands to gain
diagnostic laboratory companies; biomarker test manufacturers; genetic testing firms